Synmosa Biopharma (4114) — Capital Reinvestment Ratio
Latest as of December 2025:
0.32x
Synmosa Biopharma (4114) has a Capital Reinvestment Ratio of 0.32x as of December 2025, meaning it reinvests 0% of its operating cash flow (NT$185.72 Million) in capital expenditures (NT$59.46 Million). See cash generation quality of Synmosa Biopharma to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.32x
Capex / Operating Cash Flow
Operating Cash Flow
NT$185.72 Million
TWD
Capital Expenditures
NT$59.46 Million
TWD
Data as of
Dec 2025
Most recent filing
Synmosa Biopharma Capital Reinvestment Ratio (2015–2025)
This chart tracks Synmosa Biopharma's Capital Reinvestment Ratio across 9 annual periods.
Annual Capital Reinvestment Ratio for Synmosa Biopharma (2015–2025)
Year-by-year Capital Reinvestment Ratio for Synmosa Biopharma from 2015 to 2025. For live market cap and broader valuation context, see Synmosa Biopharma (4114) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.68x | NT$411.57 Million | NT$281.13 Million | ▲ +97.7% |
| 2024 | 0.35x | NT$780.62 Million | NT$269.65 Million | ▼ -34.4% |
| 2023 | 0.53x | NT$511.93 Million | NT$269.77 Million | ▲ +156.9% |
| 2022 | 0.21x | NT$630.25 Million | NT$129.29 Million | ▼ -2.1% |
| 2021 | 0.21x | NT$444.29 Million | NT$93.06 Million | ▼ -65.5% |
| 2020 | 0.61x | NT$254.40 Million | NT$154.41 Million | ▼ -96.9% |
| 2018 | 19.66x | NT$16.00 Million | NT$314.43 Million | ▲ +996.6% |
| 2016 | 1.79x | NT$236.48 Million | NT$423.92 Million | ▼ -88.5% |
| 2015 | 15.65x | NT$23.60 Million | NT$369.26 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow